Citigroup Inc. Buys 7,670 Shares of IDEXX Laboratories, Inc. $IDXX

Citigroup Inc. boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.6% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 144,452 shares of the company’s stock after purchasing an additional 7,670 shares during the period. Citigroup Inc. owned about 0.18% of IDEXX Laboratories worth $92,289,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $30,000. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories in the 3rd quarter valued at about $31,000. Armstrong Advisory Group Inc. lifted its position in IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after acquiring an additional 19 shares during the last quarter. Salomon & Ludwin LLC bought a new stake in shares of IDEXX Laboratories during the third quarter worth approximately $35,000. Finally, Greykasell Wealth Strategies Inc. acquired a new position in shares of IDEXX Laboratories in the third quarter valued at approximately $35,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Sophie V. Vandebroek sold 1,464 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total transaction of $920,299.68. Following the sale, the director owned 648 shares in the company, valued at $407,345.76. The trade was a 69.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Michael G. Erickson sold 5,371 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the transaction, the executive vice president directly owned 12,693 shares of the company’s stock, valued at approximately $7,963,334.34. The trade was a 29.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 18,180 shares of company stock worth $11,626,996 in the last 90 days. Insiders own 0.98% of the company’s stock.

Key Headlines Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Analyst support remains a tailwind — multiple firms continue to rate IDXX favorably (Jefferies, BTIG, Barclays among others) and the consensus remains a “Moderate Buy” with a material above‑current price target consensus. That analyst backdrop can support buying interest. Read More.
• Neutral Sentiment: Company fundamentals: IDXX reported a slight EPS miss (by $0.01) for the most recent quarter but beat on revenue (+14% y/y) and provided FY‑2026 EPS guidance of $14.29–$14.80 — guidance is above many near‑term expectations, which is generally constructive for the stock. Read More.
• Neutral Sentiment: Re‑rating narrative: recent commentary (Conestoga/InsiderMonkey, Yahoo syndicated pieces) argues IDXX shares are re‑rating toward historical averages — this is discussion‑driven and could help multiple investors re‑allocate into the name if the argument gains traction. Read More.
• Neutral Sentiment: Comparisons in the sector: valuation/sector pieces (e.g., Zacks comparing SONVY vs IDXX) may influence relative‑value flows but don’t present new company‑specific catalysts. Read More.
• Neutral Sentiment: Short‑interest data posted for February appears to show zero shares / zero days‑to‑cover (likely a reporting anomaly). That suggests no clear short‑squeeze pressure at present but verify with exchange short‑interest releases.
• Negative Sentiment: Insider selling: multiple execs disclosed sizable sales on Feb 17 — Director Sophie Vandebroek sold 1,464 shares (~$628.62 avg) and EVP Michael Erickson sold 5,371 shares (~$627.38 avg). Large insider sales can be read as signal of personal liquidity/positioning and may weigh on near‑term sentiment. Read More. Read More.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Leerink Partners set a $785.00 price target on IDEXX Laboratories in a report on Monday, November 3rd. Stifel Nicolaus set a $775.00 target price on IDEXX Laboratories in a report on Monday, November 3rd. JPMorgan Chase & Co. boosted their target price on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Finally, Barclays dropped their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $783.33.

IDEXX Laboratories Price Performance

IDXX stock opened at $635.66 on Monday. The company has a 50 day simple moving average of $677.74 and a 200 day simple moving average of $669.32. The stock has a market cap of $50.76 billion, a price-to-earnings ratio of 48.64, a P/E/G ratio of 3.87 and a beta of 1.67. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.